- Home
- ASA vs MYGN Comparison
ASA vs MYGN Comparison
Compare ASA & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASA
- MYGN
- Stock Information
- Founded
- ASA 1958
- MYGN 1991
- Country
- ASA United States
- MYGN United States
- Employees
- ASA N/A
- MYGN N/A
- Industry
- ASA Precious Metals
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- ASA Industrials
- MYGN Health Care
- Exchange
- ASA Nasdaq
- MYGN Nasdaq
- Market Cap
- ASA 622.9M
- MYGN 744.7M
- IPO Year
- ASA N/A
- MYGN 1995
- Fundamental
- Price
- ASA $31.58
- MYGN $5.22
- Analyst Decision
- ASA
- MYGN Hold
- Analyst Count
- ASA 0
- MYGN 15
- Target Price
- ASA N/A
- MYGN $15.14
- AVG Volume (30 Days)
- ASA 52.6K
- MYGN 2.0M
- Earning Date
- ASA 07-07-2025
- MYGN 08-05-2025
- Dividend Yield
- ASA 0.13%
- MYGN N/A
- EPS Growth
- ASA N/A
- MYGN N/A
- EPS
- ASA 11.67
- MYGN N/A
- Revenue
- ASA $3,557,386.00
- MYGN $831,300,000.00
- Revenue This Year
- ASA N/A
- MYGN N/A
- Revenue Next Year
- ASA N/A
- MYGN $6.68
- P/E Ratio
- ASA $2.71
- MYGN N/A
- Revenue Growth
- ASA 45.39
- MYGN 7.38
- 52 Week Low
- ASA $17.08
- MYGN $3.81
- 52 Week High
- ASA $35.00
- MYGN $29.30
- Technical
- Relative Strength Index (RSI)
- ASA 48.37
- MYGN 52.00
- Support Level
- ASA $33.41
- MYGN $4.90
- Resistance Level
- ASA $33.50
- MYGN $5.20
- Average True Range (ATR)
- ASA 0.89
- MYGN 0.24
- MACD
- ASA -0.36
- MYGN 0.08
- Stochastic Oscillator
- ASA 19.96
- MYGN 68.85
About ASA ASA Gold and Precious Metals Limited
ASA Gold And Precious Metals Ltd is a closed-end, non-diversified investment company. Its objective is to provide long-term capital appreciation through investing in companies engaged in the exploration for, development of projects, or mining of precious metals and minerals.
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.